Can GS-101 Prevent Corneal Transplant Rejection?

September 10, 2009

Gene Signal announced the publication of interim phase II data that suggests that the antisense oligonucleotide GS-101 is safe and effective at inhibiting and regressing corneal neovascularization. This study was published in the September 2009 issue of Ophthalmology. The group that received the GS-101 dose of 86 µg/day showed regression in 86% of patients compared with progression of neovascularization which occurred in 100% of the placebo group.

Forty patients who were non-responsive to conventional therapy participated in the study. Four groups of 10 patients were treated for three months comparing three doses of GS-101 twice a day to placebo (10 patients per group). The primary endpoint was measured by the reduction in area covered by pathologic corneal blood vessels measured morphometrically on digitized slit-lamp pictures.

GS-101 was found to be well tolerated in this study.

The company is now conducting an international phase III trial with GS-101 for the prevention of pathologic corneal neovascularization and thereby corneal graft rejection. GS-101 has been granted Orphan Drug status for this indication in Europe.

Read the release.

 

 



Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/002114-gene-signal-says-gs-101-may-prevent-corneal-transplant-rejection/trackback/

Have insights to contribute? Please submit your comment below